EUVIMEDEUVIMED entdecken
Crossref

Transcatheter management of pure native aortic valve regurgitation in patients with left ventricular assist device

Hristian Hinkov iD, Chong Bin Lee, Leonard Pitts iD, Pia Lanmüller, Christoph Klein, Marian Kukucka, Evgenij Potapov, Jörg Kempfert iD, Volkmar Falk iD, Henryk Dreger, Axel Unbehaun

European Journal of Cardio-Thoracic Surgery · 01.03.2024 · 65 (3)

DOI: 10.1093/ejcts/ezae028 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Cardio-Thoracic Surgery, online erschienen am 25.01.2024. Verfasst von Hristian Hinkov und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum der Charité (DHZC), Berlin, Germany. Hauptthemen laut MEDLINE: Heart-Assist Devices, Aortic Valve Stenosis, Aortic Valve Insufficiency, Transcatheter Aortic Valve Replacement. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 19 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES Aortic valve regurgitation (AR) frequently complicates the clinical course after left ventricular assist device (LVAD) implantation. Transcatheter aortic valve implantation (TAVI) has emerged as an alternative to surgical aortic valve replacement (SAVR) in this cohort with a mostly high surgical risk profile. The unique challenges in LVAD patients, such as presence of non-calcified aortic valves and annular dilatation, raise concerns about device migration and paravalvular leakage (PVL) leading to missing device success. This study evaluates procedural outcomes and survival rates in LVAD patients who underwent TAVI, emphasizing strategies to enhance device success. METHODS Between January 2017 and April 2023, 27 LVAD patients with clinically significant AR underwent elective or urgent TAVI at our centre. Primary end-points were procedural success rates, without the need for a second transcatheter heart valve (THV) and postprocedural AR/PVL. Secondary outcomes included survival rates and adverse events. RESULTS Among the cohort, 14.8% received AR-dedicated TAVI devices, with none requiring a second THV. There was no intraprocedural AR, and 1 patient (25%) had AR > ‘trace’ at discharge. Additionally, 25.9% underwent device landing zone (DLZ) pre-stenting with a standard TAVI device, all without needing a second THV. There was no intraprocedural AR, and none to trace AR at discharge. Among the 59.3% receiving standard TAVI devices, 37.5% required a second THV. In this subgroup, intraprocedural AR > ‘trace’ occurred in 12.5%, decreasing to 6.25% at discharge. In-hospital mortality was 3.7%, and median follow-up survival was 388 days (interquartile range 208–1167 days). CONCLUSIONS TAVI yields promising procedural outcomes and early survival rates in LVAD patients with AR. Tailored TAVI devices and pre-stenting techniques enhance procedural success. Continued research into these strategies is essential to optimize outcomes in this complex patient cohort.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart-Assist DevicesAortic Valve StenosisAortic Valve InsufficiencyTranscatheter Aortic Valve ReplacementHeart Valve ProsthesisHumansAortic ValveTreatment Outcome

Stichwörter der Autor:innen

Aortic regurgitationJenaValveLeft ventricular assist devicePre-stentingTranscatheter aortic valve implantationTranscatheter aortic valve replacement

Autor:innen und Institutionen

  • Department of Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum der Charité (DHZC), Berlin, Germany.
  • Charité-Universitätsmedizin Berlin, Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • DZHK (German Center for Cardiovascular Research), Berlin, Germany.
  • Department of Internal Medicine and Cardiology, Deutsches Herzzentrum der Charité (DHZC), Berlin, Germany.
  • Department of Cardiac Anaesthesiology and Intensive Care Medicine, Deutsches Herzzentrum der Charité, Berlin, Germany.
  • Department of Health Sciences and Technology, Translational Cardiovascular Technology, ETH Zurich, Zurich, Switzerland.

ORCID-Profile: Hristian Hinkov, Leonard Pitts, Jörg Kempfert, Volkmar Falk

Zitieren

APA

Hinkov, H., Lee, C. B., Pitts, L., Lanmüller, P., Klein, C., Kukucka, M., Potapov, E., Kempfert, J., Falk, V., Dreger, H., & Unbehaun, A. (2024). Transcatheter management of pure native aortic valve regurgitation in patients with left ventricular assist device. European Journal of Cardio-Thoracic Surgery, 65(3). https://doi.org/10.1093/ejcts/ezae028

Vancouver

Hinkov H, Lee CB, Pitts L, Lanmüller P, Klein C, Kukucka M, et al. Transcatheter management of pure native aortic valve regurgitation in patients with left ventricular assist device. European Journal of Cardio-Thoracic Surgery. 2024;65(3). doi:10.1093/ejcts/ezae028

BibTeX
@article{Hinkov2024,
  author = {Hinkov, Hristian and Lee, Chong Bin and Pitts, Leonard and Lanmüller, Pia and Klein, Christoph and Kukucka, Marian and Potapov, Evgenij and Kempfert, Jörg and Falk, Volkmar and Dreger, Henryk and Unbehaun, Axel},
  title = {Transcatheter management of pure native aortic valve regurgitation in patients with left ventricular assist device},
  journal = {European Journal of Cardio-Thoracic Surgery},
  year = {2024},
  volume = {65},
  number = {3},
  doi = {10.1093/ejcts/ezae028}
}
Kostenlos starten →